Electronic lab notebooks (ELNs) were introduced to modernize laboratory work. But new research from Sapio Sciences suggests many scientists now see them as obstacles rather than enablers of discovery.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers ...
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers ...
Discover how the right excipient can support efficient processing, reliable dosing, fast dissolution and a more patient-friendly experience, and learn what galenIQ™ brings to modern sachet development ...
Moderna has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...
We are all watching the rise of oral, small molecule GLP-1 receptor agonists with justified interest. The promising phase III results of Eli Lilly’s orforglipron has set the pace, and others are ...
Debates around tariffs and wider trade tensions often center on supply chains and manufacturing, but beneath that conversation lies another, quieter shift – how these forces are reshaping the ...
The biopharmaceutical industry currently finds itself at a precarious intersection of unprecedented innovation and antiquated validation. We have unlocked unprecedented capabilities in gene editing ...
Biology may be complex, but in 2025 the industry proved it doesn’t have to be chaotic. From manufacturing CAR-T cells inside the patient to industrializing organoid platforms, the year marked a ...
Cutting carbon in pharmaceutical supply chains may depend less on how much a process emits – and more on where it sits in the network. A new study shows that structurally central players, such as ...
Welcome to our annual showcase of top technology launches this year for drug development and manufacturing! Every year, The Medicine Maker asks readers to submit their nominations for inspiring ...
The FDA has unveiled its top science and research priorities for FY 2026 under the GDUFA program, including nitrosamine risk, complex drug development, bioequivalence innovations, and the use of AI ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results